Catalyst Pharmaceuticals, Inc.

Team Catalyst is at Physicians' Education Resource®, LLC (PER®)'s 25th Annual International Lung Cancer Congress, visit our table to learn about the connection between Small Cell Lung Cancer (SCLC) and Lambert‐Eaton myasthenic syndrome (LEMS). LEMS is an autoimmune disorder that affects neuromuscular transmission. #GoToPER https://lnkd.in/gJ9-Ha83

Catalyst Pharmaceuticals, Inc. has entered into a License, Supply, and Commercialization Agreement with Kye Pharmaceuticals granting Kye the exclusive Canadian commercial rights to AGAMREE® (vamorolone), a novel corticosteroid for the treatment of #DuchenneMuscularDystrophy and potentially other indications. Learn more about this partnership and the terms of the agreement below.

Team Catalyst is at American Academy of Neurology's 2024 Summer Conference: Autoimmune Neurology. Visit Booth #13 to learn how Catalyst Pharmaceuticals, Inc. is engaged in the neurological space. #AANSC #RareDisease #Neurology

The Catalyst Team is in Chicago for the Mayo Clinic’s Neurology in Clinical Practice Conference. We proudly support today’s Product Theater on “Lambert-Eaton Myasthenic Syndrome (LEMS): An Often-Misdiagnosed Condition with Symptoms of Weakness and Fatigue” presented by Perry Shieh,M.D.,PhD. – We welcome attendees to stop by our table to discuss LEMS and learn how Catalyst serves the Neuromuscular Community. 

The therapeutic window for FIRDAPSE has expanded! https://lnkd.in/gx-T9U_5 IMPORTANT SAFETY INFORMATION: INDICATIONS AND USAGE: FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older. CONTRAINDICATIONS FIRDAPSE is contraindicated in patients with: • A history of seizures • Hypersensitivity to amifampridine phosphate or another aminopyridine WARNINGS AND PRECAUTIONS Seizures: FIRDAPSE can cause seizures. Consider discontinuation or dose-reduction of FIRDAPSE in patients who have a seizure while on treatment. Hypersensitivity: If a hypersensitivity reaction such as anaphylaxis occurs, FIRDAPSE should be discontinued and appropriate therapy initiated. ADVERSE REACTIONS The most common (> 10%) adverse reactions are: paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms. Please see full Prescribing Information: https://lnkd.in/gudBQ5wU for additional Important Safety Information. To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals at 1-844-347-3277 (1-844-FIRDAPSE) or FDA at 1-800-FDA-1088 or https://lnkd.in/gcQWcr-3.

#Happy4thOfJuly

Catalyst Pharmaceuticals, Inc. is pleased to provide the Company’s 2023 Environmental, Social, and Governance (ESG) Report. The ESG Report outlines our practices, policies, and performance on relevant ESG issues during the fiscal year. Learn more: https://lnkd.in/gx9D49fK

Team Catalyst is enjoying connecting with the DMD Community at Parent Project Muscular Dystrophy’s 30th Annual Conference. Over a thousand attendees- made up of families, researchers, clinicians, and industry partners- have come together to share information and engage in sessions covering the latest news in research, clinical trials, approved and emerging therapies, care initiatives, quality of life issues, and more. Visit our booth to learn how Catalyst is serving the DMD Community. #PPMD2024

June is #MyastheniaGravis (MG) awareness month. As MG can be misdiagnosed with Lambert-Eaton myasthenic syndrome (LEMS), take a moment to learn more about the clinical overlap between MG and #LEMS to potentially shorten a patient's diagnostic journey: https://lnkd.in/gA9fdhtZ

Many people with LEMS struggle with symptoms for years before finally getting diagnosed. It is important to see a physician who has experience with diagnosing neuromuscular diseases. An early, accurate diagnosis can be beneficial for your health. Find out how: https://lnkd.in/gh_-r_s6 IMPORTANT SAFETY INFORMATION: INDICATIONS AND USAGE: FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older. CONTRAINDICATIONS FIRDAPSE is contraindicated in patients with: • A history of seizures • Hypersensitivity to amifampridine phosphate or another aminopyridine WARNINGS AND PRECAUTIONS Seizures: FIRDAPSE can cause seizures. Consider discontinuation or dose-reduction of FIRDAPSE in patients who have a seizure while on treatment. Hypersensitivity: If a hypersensitivity reaction such as anaphylaxis occurs, FIRDAPSE should be discontinued and appropriate therapy initiated. ADVERSE REACTIONS The most common (> 10%) adverse reactions are: paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms. Please see full Prescribing Information: https://lnkd.in/gqN8Rund for additional Important Safety Information. To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals at 1-844-347-3277 (1-844-FIRDAPSE) or FDA at 1-800-FDA-1088 or https://lnkd.in/gcQWcr-3.